Sanofi: EU approves Xenpozyme
(CercleFinance.com) - Sanofi announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion and recommended the marketing of Xenpozyme.
The biopharmaceutical company said that this green light relates to the approval of Xenpozyme in the non-neurological manifestations of acid sphingomyelinase type A/B and type B deficiency.
The CHMP opinion is based on the positive results of two clinical trials that demonstrated that Xenpozyme improved respiratory function and reduced spleen and liver volume, with a well-tolerated safety profile.
Xenpozyme is a recombinant human enzyme developed to address the deficiency of acid sphingomyelinase, the enzyme that breaks down the lipid sphingomyelin.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The biopharmaceutical company said that this green light relates to the approval of Xenpozyme in the non-neurological manifestations of acid sphingomyelinase type A/B and type B deficiency.
The CHMP opinion is based on the positive results of two clinical trials that demonstrated that Xenpozyme improved respiratory function and reduced spleen and liver volume, with a well-tolerated safety profile.
Xenpozyme is a recombinant human enzyme developed to address the deficiency of acid sphingomyelinase, the enzyme that breaks down the lipid sphingomyelin.
Copyright (c) 2022 CercleFinance.com. All rights reserved.